{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T01:20:26Z","timestamp":1790385626366,"version":"4.1.0"},"reference-count":14,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2008,8,29]],"date-time":"2008-08-29T00:00:00Z","timestamp":1219968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2008,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the efficacy of pegloticase in achieving and maintaining plasma urate levels of &lt;6 mg\/dl in gout patients in whom other treatments have failed, and to assess the pharmacokinetics and safety of pegloticase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Forty\u2010one patients were randomized to undergo 12\u201314 weeks of treatment with pegloticase at 1 of 4 dosage levels: 4 mg every 2 weeks, 8 mg every 2 weeks, 8 mg every 4 weeks, or 12 mg every 4 weeks. Plasma uricase activity, plasma urate, and antipegloticase antibodies were measured, pharmacokinetic parameters were assessed, and adverse events were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The mean plasma urate level was reduced to \u22646 mg\/dl within 6 hours in all dosage groups, and this was sustained throughout the treatment period in the 8 mg and 12 mg dosage groups. The most effective dosage was 8 mg every 2 weeks. Twenty\u2010six patients received all protocol doses. The percentage of the patients in whom the primary efficacy end point (plasma urate &lt;6 mg\/dl for 80% of the study period) was achieved ranged from 50% to 88%. Gout flares occurred in 88% of the patients. The majority of adverse events (excluding gout flare) were unrelated to treatment and were mild or moderate in severity. Infusion\u2010day adverse events were the most common reason for study withdrawal (12 of 15 withdrawals). There were no anaphylactic reactions. Antipegloticase antibody, present in 31 of 41 patients, was associated with reduced circulating half\u2010life of pegloticase in some patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pegloticase, administered in multiple doses, was effective in rapidly reducing and maintaining plasma urate levels at \u22646 mg\/dl in most patients in whom conventional therapy had been unsuccessful due to lack of response, intolerability, or contraindication.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.23810","type":"journal-article","created":{"date-parts":[[2008,8,29]],"date-time":"2008-08-29T16:46:07Z","timestamp":1220028367000},"page":"2882-2891","source":"Crossref","is-referenced-by-count":147,"title":["Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol\u2013conjugated uricase) in patients with treatment\u2010failure gout: Results of a phase II randomized study"],"prefix":"10.1002","volume":"58","author":[{"given":"John S.","family":"Sundy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert S. B.","family":"Baraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Barkhuizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry W.","family":"Moreland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Royce W.","family":"Waltrip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan N.","family":"Maroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeb","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Pegloticase Phase 2 Study Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,8,29]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"2303","volume-title":"Arthritis and allied conditions: a textbook of rheumatology","author":"Becker MA","year":"2005"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10511"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20405"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050373"},{"key":"e_1_2_7_6_2","first-page":"ii93","article-title":"The FOCUS trial 48\u2010month interim analysis: long\u2010term clinical outcomes of treatment with febuxostat in subjects with gout in an ongoing phase 2, open\u2010label extension study","volume":"65","author":"Schumacher HR","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-007-0041-y"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar1861"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22403"},{"key":"e_1_2_7_10_2","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/clinchem\/26.2.227","article-title":"Use of 3,5\u2010dichloro\u20102\u20102\u2010hydroxybenzesulfonic acid\/4\u2010aminophenazone chromogenic system in direct enzymatic assay of uric acid in serum and urine","volume":"26","author":"Fossati P","year":"1980","journal-title":"Clin Chem"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-7963(03)00038-5"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2004.04.002"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200405030-00003"},{"key":"e_1_2_7_14_2","unstructured":"Remicade prescribing information. URL:www.centocor.com\/centocor\/assets\/remicade.pdf#zoom=100. Centocor Inc. April2007."},{"key":"e_1_2_7_15_2","unstructured":"Rituxan prescribing information. URL:www.gene.com\/gene\/ products\/information\/immunological\/rituxan\/insert.jsp. Biogen Idec Inc. and Genentech Inc. August2007."}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.23810","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.23810","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T19:23:01Z","timestamp":1696965781000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.23810"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,29]]},"references-count":14,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["10.1002\/art.23810"],"URL":"https:\/\/doi.org\/10.1002\/art.23810","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1123806.580891","asserted-by":"object"}]},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,29]]}}}